Skye Bioscience, Common Stock Buy Hold or Sell Recommendation
| SKYE Stock | USD 2.86 0.15 4.98% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Skye Bioscience, Common is 'Cautious Hold'. Macroaxis provides Skye Bioscience, buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SKYE positions.
Check out Skye Bioscience, Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Skye and provide practical buy, sell, or hold advice based on investors' constraints. Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Skye |
Execute Skye Bioscience, Buy or Sell Advice
The Skye recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Skye Bioscience, Common. Macroaxis does not own or have any residual interests in Skye Bioscience, Common or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Skye Bioscience,'s advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Skye Bioscience, Trading Alerts and Improvement Suggestions
| Skye Bioscience, generated a negative expected return over the last 90 days | |
| Skye Bioscience, has high historical volatility and very poor performance | |
| Skye Bioscience, Common currently holds 4.62 M in liabilities with Debt to Equity (D/E) ratio of 0.84, which is about average as compared to similar companies. Skye Bioscience, Common has a current ratio of 0.89, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Skye Bioscience,'s use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (37.64 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Skye Bioscience, Common currently holds about 2.93 M in cash with (13.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Skye Bioscience, has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of Skye Bioscience, shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Skye Bioscience to Present at J.P. Morgan Healthcare Conference |
Skye Bioscience, Returns Distribution Density
The distribution of Skye Bioscience,'s historical returns is an attempt to chart the uncertainty of Skye Bioscience,'s future price movements. The chart of the probability distribution of Skye Bioscience, daily returns describes the distribution of returns around its average expected value. We use Skye Bioscience, Common price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Skye Bioscience, returns is essential to provide solid investment advice for Skye Bioscience,.
| Mean Return | -0.58 | Value At Risk | -7.88 | Potential Upside | 9.46 | Standard Deviation | 7.54 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Skye Bioscience, historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Skye Bioscience, Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| End Period Cash Flow | 1.8M | 2.5M | 9.0M | 1.2M | 10.3M | 10.9M | |
| Change To Netincome | 15.1M | (8.0M) | (133.5K) | 772.4K | 695.2K | 983.0K | |
| Investments | 0.0 | (7.2K) | (90.9K) | 5.2M | 6.6M | 6.9M | |
| Change In Cash | (23.4K) | 639.5K | 6.5M | (7.7M) | 9.1M | 9.5M | |
| Free Cash Flow | (6.0M) | (6.1M) | (6.6M) | (12.8M) | (14.0M) | (13.3M) | |
| Depreciation | 1.5K | 1.9K | 34.1K | 115.0K | 124.3K | 130.5K | |
| Other Non Cash Items | 629.3K | 544.0K | 593.8K | 6.8M | 23.1M | 24.2M | |
| Net Income | 1.1M | (6.6M) | (8.5M) | (19.5M) | (37.6M) | (35.8M) |
Skye Bioscience, Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Skye Bioscience, or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Skye Bioscience,'s price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Skye stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.61 | |
β | Beta against Dow Jones | 0.89 | |
σ | Overall volatility | 5.29 | |
Ir | Information ratio | -0.08 |
Skye Bioscience, Volatility Alert
Skye Bioscience, Common is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Skye Bioscience,'s stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Skye Bioscience,'s stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Skye Bioscience, Fundamentals Vs Peers
Comparing Skye Bioscience,'s fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Skye Bioscience,'s direct or indirect competition across all of the common fundamentals between Skye Bioscience, and the related equities. This way, we can detect undervalued stocks with similar characteristics as Skye Bioscience, or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Skye Bioscience,'s fundamental indicators could also be used in its relative valuation, which is a method of valuing Skye Bioscience, by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Skye Bioscience, to competition |
| Fundamentals | Skye Bioscience, | Peer Average |
| Return On Equity | -0.55 | -0.31 |
| Return On Asset | -0.3 | -0.14 |
| Current Valuation | 19.55 M | 16.62 B |
| Shares Outstanding | 30.34 M | 571.82 M |
| Shares Owned By Insiders | 1.89 % | 10.09 % |
| Shares Owned By Institutions | 85.41 % | 39.21 % |
| Number Of Shares Shorted | 1.59 M | 4.71 M |
| Price To Book | 1.14 X | 9.51 X |
| EBITDA | (13.55 M) | 3.9 B |
| Net Income | (37.64 M) | 570.98 M |
| Cash And Equivalents | 2.93 M | 2.7 B |
| Cash Per Share | 0.01 X | 5.01 X |
| Total Debt | 4.62 M | 5.32 B |
| Debt To Equity | 0.84 % | 48.70 % |
| Current Ratio | 0.91 X | 2.16 X |
| Book Value Per Share | 2.50 X | 1.93 K |
| Cash Flow From Operations | (13.95 M) | 971.22 M |
| Short Ratio | 5.76 X | 4.00 X |
| Earnings Per Share | (3.60) X | 3.12 X |
| Target Price | 18.0 | |
| Number Of Employees | 11 | 18.84 K |
| Beta | 1.75 | -0.15 |
| Market Capitalization | 163.52 M | 19.03 B |
| Total Asset | 11.94 M | 29.47 B |
| Retained Earnings | (104.38 M) | 9.33 B |
| Working Capital | (2.25 M) | 1.48 B |
| Net Asset | 11.94 M |
Note: Insider Trading [view details]
Skye Bioscience, Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Skye . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Skye Bioscience, Buy or Sell Advice
When is the right time to buy or sell Skye Bioscience, Common? Buying financial instruments such as Skye Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Skye Bioscience, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sovereign ETFs Thematic Idea Now
Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sovereign ETFs theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Skye Bioscience, Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.